KA/EN
Register
Medicines reference
Search
Search
Active substance

Selamectin

Favourites

Macrocyclic lactone (avermectin). Registered in Georgia: 15 veterinary products. Forms: spot-on.

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Selamectin
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
6 mg/kg Dog, Cat Maintenance On the skin monthly
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Stronghold 15 mg spot-on solution for cats and dogs <= 2.5 kg - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
Before use

Safety information

Known Contraindications

  • Critical
    Do not use in animals under 6 weeks of age.
    Sources: VMD SPC · VMD
  • Critical
    Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
    Sources: VMD SPC · VMD
  • Warning (Cat)
    Do not use in cats that are suffering from concomitant disease, or are debilitated and underweight (for size and age).
    Sources: VMD SPC · VMD
Latin name
Selamectin
Georgian name
სელამექტინი
Authorisation status
Authorised veterinary medicine
An authorised veterinary medicine containing this substance exists. Whether a particular use is on-label depends on the species and the indication - see each dose rule.
Registered in Georgia
15 of 15 forms
Products
Evicto, Stronghold, Stronghold Plus
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration15

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Evicto 15 mg, Spot-on

selamectin 15 mg (60 mg/ml), spot-on solution for cats and dogs up to 2.5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Full labelled species-specific scope for treatment or prevention of susceptible flea, mite, nematode and heartworm targets
8.4/10
Very good
vetman assessment

Evicto

15 mg, selamectin 15 mg (60 mg/ml), spot-on solution for cats and dogs up to 2.5 kg
Assessed clinical scopeDog · Full labelled species-specific scope for treatment or prevention of susceptible flea, mite, nematode and heartworm targets · On the skin
Care settingMonthly or indication-specific single-pipette spot-on treatment after exact species, weight, parasite and heartworm-risk assessment
vetman score 8.4/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 71-11 · Verified on 15 Oct 2026

A well-supported centrally authorised generic with the same established selamectin role and practical dosing; its evidence rests mainly on bioequivalence and the reference product rather than exact-brand outcome trials.

Regulatory and scientific credibility8.5/10

Every exact presentation is registered in Georgia; Evicto has a current central EU/UK generic authorisation supported by satisfactory quality and bioequivalence to Stronghold.

Clinical efficacy8.5/10

Efficacy is bridged to the established selamectin reference product through the generic dossier and bioequivalence; the active has strong field evidence, although independent exact-Evicto outcome trials are limited.

Safety and tolerability8.0/10

The safety margin is well characterised and generally favourable, but species/weight mismatch, very young age, debilitated or underweight cats, wet or damaged skin, ingestion and heavily microfilaraemic dogs require specific precautions.

Clinical practicality8.5/10

A premeasured monthly pipette is simple and avoids oral administration, but correct skin exposure, full-pipette delivery, drying time and prevention of licking are necessary for reliable use.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only the exact species and weight-band pipette; do not split a pipette or substitute dog and cat presentations solely by milligram strength.
  • Do not use below six weeks of age or on wet, broken or otherwise unsuitable application skin; observe the locally applicable exact label.
  • Apply the complete pipette directly to exposed skin, prevent licking and close contact until dry, and keep away from flame or ignition sources during drying.
  • Confirm the target parasite and repeat interval; investigate apparent failure for application technique, bathing, reinfection and resistance rather than empirically increasing dose.
  • For heartworm prevention, test according to local epidemiology and the exact label; heavily microfilaraemic dogs require veterinary assessment and monitoring for acute reactions.
Assessment sources
  1. VMD SPC 20242024
  2. EMA Evicto opinion2019
  3. Selamectin flea/HW field trials2000
  4. Selamectin mite field trials2000
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Full labelled species-specific scope for treatment or prevention of susceptible flea, mite, nematode and heartworm targets
8.4/10
Very good
vetman assessment

Evicto

15 mg, selamectin 15 mg (60 mg/ml), spot-on solution for cats and dogs up to 2.5 kg
Assessed clinical scopeCat · Full labelled species-specific scope for treatment or prevention of susceptible flea, mite, nematode and heartworm targets · On the skin
Care settingMonthly or indication-specific single-pipette spot-on treatment after exact species, weight, parasite and heartworm-risk assessment
vetman score 8.4/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 71-11 · Verified on 15 Oct 2026

A well-supported centrally authorised generic with the same established selamectin role and practical dosing; its evidence rests mainly on bioequivalence and the reference product rather than exact-brand outcome trials.

Regulatory and scientific credibility8.5/10

Every exact presentation is registered in Georgia; Evicto has a current central EU/UK generic authorisation supported by satisfactory quality and bioequivalence to Stronghold.

Clinical efficacy8.5/10

Efficacy is bridged to the established selamectin reference product through the generic dossier and bioequivalence; the active has strong field evidence, although independent exact-Evicto outcome trials are limited.

Safety and tolerability8.0/10

The safety margin is well characterised and generally favourable, but species/weight mismatch, very young age, debilitated or underweight cats, wet or damaged skin, ingestion and heavily microfilaraemic dogs require specific precautions.

Clinical practicality8.5/10

A premeasured monthly pipette is simple and avoids oral administration, but correct skin exposure, full-pipette delivery, drying time and prevention of licking are necessary for reliable use.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only the exact species and weight-band pipette; do not split a pipette or substitute dog and cat presentations solely by milligram strength.
  • Do not use below six weeks of age or on wet, broken or otherwise unsuitable application skin; observe the locally applicable exact label.
  • Apply the complete pipette directly to exposed skin, prevent licking and close contact until dry, and keep away from flame or ignition sources during drying.
  • Confirm the target parasite and repeat interval; investigate apparent failure for application technique, bathing, reinfection and resistance rather than empirically increasing dose.
  • Do not use in cats with concomitant disease or in debilitated or underweight cats unless the exact locally applicable label and a veterinarian-led benefit-risk decision permit use.
Assessment sources
  1. VMD SPC 20242024
  2. EMA Evicto opinion2019
  3. Selamectin flea/HW field trials2000
  4. Selamectin mite field trials2000
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Selamectin15 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
Virbac · France
Manufacturer (register)
VIRBAC, France
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1043, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ევიქტო® 15მგ
№ 71-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Evicto 30 mg, Spot-on

selamectin 30 mg (120 mg/ml), spot-on solution for dogs 2.6-5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.4/10
Very good
vetman assessment

Evicto

30 mg, selamectin 30 mg (120 mg/ml), spot-on solution for dogs 2.6-5 kg
Assessed clinical scopeDog · Full labelled species-specific scope for treatment or prevention of susceptible flea, mite, nematode and heartworm targets · On the skin
Care settingMonthly or indication-specific single-pipette spot-on treatment after exact species, weight, parasite and heartworm-risk assessment
vetman score 8.4/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 75-11 · Verified on 15 Oct 2026

A well-supported centrally authorised generic with the same established selamectin role and practical dosing; its evidence rests mainly on bioequivalence and the reference product rather than exact-brand outcome trials.

Regulatory and scientific credibility8.5/10

Every exact presentation is registered in Georgia; Evicto has a current central EU/UK generic authorisation supported by satisfactory quality and bioequivalence to Stronghold.

Clinical efficacy8.5/10

Efficacy is bridged to the established selamectin reference product through the generic dossier and bioequivalence; the active has strong field evidence, although independent exact-Evicto outcome trials are limited.

Safety and tolerability8.0/10

The safety margin is well characterised and generally favourable, but species/weight mismatch, very young age, debilitated or underweight cats, wet or damaged skin, ingestion and heavily microfilaraemic dogs require specific precautions.

Clinical practicality8.5/10

A premeasured monthly pipette is simple and avoids oral administration, but correct skin exposure, full-pipette delivery, drying time and prevention of licking are necessary for reliable use.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only the exact species and weight-band pipette; do not split a pipette or substitute dog and cat presentations solely by milligram strength.
  • Do not use below six weeks of age or on wet, broken or otherwise unsuitable application skin; observe the locally applicable exact label.
  • Apply the complete pipette directly to exposed skin, prevent licking and close contact until dry, and keep away from flame or ignition sources during drying.
  • Confirm the target parasite and repeat interval; investigate apparent failure for application technique, bathing, reinfection and resistance rather than empirically increasing dose.
  • For heartworm prevention, test according to local epidemiology and the exact label; heavily microfilaraemic dogs require veterinary assessment and monitoring for acute reactions.
Assessment sources
  1. VMD SPC 20242024
  2. EMA Evicto opinion2019
  3. Selamectin flea/HW field trials2000
  4. Selamectin mite field trials2000
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Selamectin30 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
Virbac · France
Manufacturer (register)
VIRBAC, France
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1046, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ევიქტო® 30მგ
№ 75-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Evicto 45 mg, Spot-on

selamectin 45 mg (60 mg/ml), spot-on solution for cats 2.6-7.5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
8.4/10
Very good
vetman assessment

Evicto

45 mg, selamectin 45 mg (60 mg/ml), spot-on solution for cats 2.6-7.5 kg
Assessed clinical scopeCat · Full labelled species-specific scope for treatment or prevention of susceptible flea, mite, nematode and heartworm targets · On the skin
Care settingMonthly or indication-specific single-pipette spot-on treatment after exact species, weight, parasite and heartworm-risk assessment
vetman score 8.4/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 78-11 · Verified on 15 Oct 2026

A well-supported centrally authorised generic with the same established selamectin role and practical dosing; its evidence rests mainly on bioequivalence and the reference product rather than exact-brand outcome trials.

Regulatory and scientific credibility8.5/10

Every exact presentation is registered in Georgia; Evicto has a current central EU/UK generic authorisation supported by satisfactory quality and bioequivalence to Stronghold.

Clinical efficacy8.5/10

Efficacy is bridged to the established selamectin reference product through the generic dossier and bioequivalence; the active has strong field evidence, although independent exact-Evicto outcome trials are limited.

Safety and tolerability8.0/10

The safety margin is well characterised and generally favourable, but species/weight mismatch, very young age, debilitated or underweight cats, wet or damaged skin, ingestion and heavily microfilaraemic dogs require specific precautions.

Clinical practicality8.5/10

A premeasured monthly pipette is simple and avoids oral administration, but correct skin exposure, full-pipette delivery, drying time and prevention of licking are necessary for reliable use.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only the exact species and weight-band pipette; do not split a pipette or substitute dog and cat presentations solely by milligram strength.
  • Do not use below six weeks of age or on wet, broken or otherwise unsuitable application skin; observe the locally applicable exact label.
  • Apply the complete pipette directly to exposed skin, prevent licking and close contact until dry, and keep away from flame or ignition sources during drying.
  • Confirm the target parasite and repeat interval; investigate apparent failure for application technique, bathing, reinfection and resistance rather than empirically increasing dose.
  • Do not use in cats with concomitant disease or in debilitated or underweight cats unless the exact locally applicable label and a veterinarian-led benefit-risk decision permit use.
Assessment sources
  1. VMD SPC 20242024
  2. EMA Evicto opinion2019
  3. Selamectin flea/HW field trials2000
  4. Selamectin mite field trials2000
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Selamectin45 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
Virbac · France
Manufacturer (register)
VIRBAC, France
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1048, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ევიქტო® 45მგ
№ 78-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Evicto 60 mg, Spot-on

selamectin 60 mg (120 mg/ml), spot-on solution for dogs 5.1-10 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.4/10
Very good
vetman assessment

Evicto

60 mg, selamectin 60 mg (120 mg/ml), spot-on solution for dogs 5.1-10 kg
Assessed clinical scopeDog · Full labelled species-specific scope for treatment or prevention of susceptible flea, mite, nematode and heartworm targets · On the skin
Care settingMonthly or indication-specific single-pipette spot-on treatment after exact species, weight, parasite and heartworm-risk assessment
vetman score 8.4/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 72-11 · Verified on 15 Oct 2026

A well-supported centrally authorised generic with the same established selamectin role and practical dosing; its evidence rests mainly on bioequivalence and the reference product rather than exact-brand outcome trials.

Regulatory and scientific credibility8.5/10

Every exact presentation is registered in Georgia; Evicto has a current central EU/UK generic authorisation supported by satisfactory quality and bioequivalence to Stronghold.

Clinical efficacy8.5/10

Efficacy is bridged to the established selamectin reference product through the generic dossier and bioequivalence; the active has strong field evidence, although independent exact-Evicto outcome trials are limited.

Safety and tolerability8.0/10

The safety margin is well characterised and generally favourable, but species/weight mismatch, very young age, debilitated or underweight cats, wet or damaged skin, ingestion and heavily microfilaraemic dogs require specific precautions.

Clinical practicality8.5/10

A premeasured monthly pipette is simple and avoids oral administration, but correct skin exposure, full-pipette delivery, drying time and prevention of licking are necessary for reliable use.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only the exact species and weight-band pipette; do not split a pipette or substitute dog and cat presentations solely by milligram strength.
  • Do not use below six weeks of age or on wet, broken or otherwise unsuitable application skin; observe the locally applicable exact label.
  • Apply the complete pipette directly to exposed skin, prevent licking and close contact until dry, and keep away from flame or ignition sources during drying.
  • Confirm the target parasite and repeat interval; investigate apparent failure for application technique, bathing, reinfection and resistance rather than empirically increasing dose.
  • For heartworm prevention, test according to local epidemiology and the exact label; heavily microfilaraemic dogs require veterinary assessment and monitoring for acute reactions.
Assessment sources
  1. VMD SPC 20242024
  2. EMA Evicto opinion2019
  3. Selamectin flea/HW field trials2000
  4. Selamectin mite field trials2000
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Selamectin60 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
Virbac · France
Manufacturer (register)
VIRBAC, France
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1044, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ევიქტო® 60მგ
№ 72-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Evicto 120 mg, Spot-on

selamectin 120 mg (120 mg/ml), spot-on solution for dogs 10.1-20 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.4/10
Very good
vetman assessment

Evicto

120 mg, selamectin 120 mg (120 mg/ml), spot-on solution for dogs 10.1-20 kg
Assessed clinical scopeDog · Full labelled species-specific scope for treatment or prevention of susceptible flea, mite, nematode and heartworm targets · On the skin
Care settingMonthly or indication-specific single-pipette spot-on treatment after exact species, weight, parasite and heartworm-risk assessment
vetman score 8.4/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 158-11 · Verified on 15 Oct 2026

A well-supported centrally authorised generic with the same established selamectin role and practical dosing; its evidence rests mainly on bioequivalence and the reference product rather than exact-brand outcome trials.

Regulatory and scientific credibility8.5/10

Every exact presentation is registered in Georgia; Evicto has a current central EU/UK generic authorisation supported by satisfactory quality and bioequivalence to Stronghold.

Clinical efficacy8.5/10

Efficacy is bridged to the established selamectin reference product through the generic dossier and bioequivalence; the active has strong field evidence, although independent exact-Evicto outcome trials are limited.

Safety and tolerability8.0/10

The safety margin is well characterised and generally favourable, but species/weight mismatch, very young age, debilitated or underweight cats, wet or damaged skin, ingestion and heavily microfilaraemic dogs require specific precautions.

Clinical practicality8.5/10

A premeasured monthly pipette is simple and avoids oral administration, but correct skin exposure, full-pipette delivery, drying time and prevention of licking are necessary for reliable use.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only the exact species and weight-band pipette; do not split a pipette or substitute dog and cat presentations solely by milligram strength.
  • Do not use below six weeks of age or on wet, broken or otherwise unsuitable application skin; observe the locally applicable exact label.
  • Apply the complete pipette directly to exposed skin, prevent licking and close contact until dry, and keep away from flame or ignition sources during drying.
  • Confirm the target parasite and repeat interval; investigate apparent failure for application technique, bathing, reinfection and resistance rather than empirically increasing dose.
  • For heartworm prevention, test according to local epidemiology and the exact label; heavily microfilaraemic dogs require veterinary assessment and monitoring for acute reactions.
Assessment sources
  1. VMD SPC 20242024
  2. EMA Evicto opinion2019
  3. Selamectin flea/HW field trials2000
  4. Selamectin mite field trials2000
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Selamectin120 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
Virbac · France
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ევიქტო® 120მგ
№ 158-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Evicto 240 mg, Spot-on

selamectin 240 mg (120 mg/ml), spot-on solution for dogs 20.1-40 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.4/10
Very good
vetman assessment

Evicto

240 mg, selamectin 240 mg (120 mg/ml), spot-on solution for dogs 20.1-40 kg
Assessed clinical scopeDog · Full labelled species-specific scope for treatment or prevention of susceptible flea, mite, nematode and heartworm targets · On the skin
Care settingMonthly or indication-specific single-pipette spot-on treatment after exact species, weight, parasite and heartworm-risk assessment
vetman score 8.4/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 73-11 · Verified on 15 Oct 2026

A well-supported centrally authorised generic with the same established selamectin role and practical dosing; its evidence rests mainly on bioequivalence and the reference product rather than exact-brand outcome trials.

Regulatory and scientific credibility8.5/10

Every exact presentation is registered in Georgia; Evicto has a current central EU/UK generic authorisation supported by satisfactory quality and bioequivalence to Stronghold.

Clinical efficacy8.5/10

Efficacy is bridged to the established selamectin reference product through the generic dossier and bioequivalence; the active has strong field evidence, although independent exact-Evicto outcome trials are limited.

Safety and tolerability8.0/10

The safety margin is well characterised and generally favourable, but species/weight mismatch, very young age, debilitated or underweight cats, wet or damaged skin, ingestion and heavily microfilaraemic dogs require specific precautions.

Clinical practicality8.5/10

A premeasured monthly pipette is simple and avoids oral administration, but correct skin exposure, full-pipette delivery, drying time and prevention of licking are necessary for reliable use.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only the exact species and weight-band pipette; do not split a pipette or substitute dog and cat presentations solely by milligram strength.
  • Do not use below six weeks of age or on wet, broken or otherwise unsuitable application skin; observe the locally applicable exact label.
  • Apply the complete pipette directly to exposed skin, prevent licking and close contact until dry, and keep away from flame or ignition sources during drying.
  • Confirm the target parasite and repeat interval; investigate apparent failure for application technique, bathing, reinfection and resistance rather than empirically increasing dose.
  • For heartworm prevention, test according to local epidemiology and the exact label; heavily microfilaraemic dogs require veterinary assessment and monitoring for acute reactions.
Assessment sources
  1. VMD SPC 20242024
  2. EMA Evicto opinion2019
  3. Selamectin flea/HW field trials2000
  4. Selamectin mite field trials2000
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Selamectin240 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
Virbac · France
Manufacturer (register)
VIRBAC, France
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1045, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ევიქტო® 240მგ
№ 73-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Stronghold 15 mg, Spot-on

selamectin 15 mg (60 mg/ml), spot-on solution for cats and dogs up to 2.5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Full labelled species-specific scope for treatment or prevention of susceptible flea, mite, nematode and heartworm targets
8.6/10
Very good
vetman assessment

Stronghold

15 mg, selamectin 15 mg (60 mg/ml), spot-on solution for cats and dogs up to 2.5 kg
Assessed clinical scopeDog · Full labelled species-specific scope for treatment or prevention of susceptible flea, mite, nematode and heartworm targets · On the skin
Care settingMonthly or indication-specific single-pipette spot-on treatment after exact species, weight, parasite and heartworm-risk assessment
vetman score 8.6/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 274-11 · Verified on 15 Oct 2026

A mature, strongly supported broad endectocide for dogs and cats with convenient monthly topical dosing and well-defined species-specific label roles.

Regulatory and scientific credibility9.0/10

Every exact presentation is registered in Georgia and the reference product has mature current EU/UK and FDA authorisations.

Clinical efficacy9.0/10

Large randomized masked field programmes support high efficacy for fleas, heartworm prevention and labelled mite targets across dogs and cats, with extensive long-term clinical use.

Safety and tolerability8.0/10

The safety margin is well characterised and generally favourable, but species/weight mismatch, very young age, debilitated or underweight cats, wet or damaged skin, ingestion and heavily microfilaraemic dogs require specific precautions.

Clinical practicality8.5/10

A premeasured monthly pipette is simple and avoids oral administration, but correct skin exposure, full-pipette delivery, drying time and prevention of licking are necessary for reliable use.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only the exact species and weight-band pipette; do not split a pipette or substitute dog and cat presentations solely by milligram strength.
  • Do not use below six weeks of age or on wet, broken or otherwise unsuitable application skin; observe the locally applicable exact label.
  • Apply the complete pipette directly to exposed skin, prevent licking and close contact until dry, and keep away from flame or ignition sources during drying.
  • Confirm the target parasite and repeat interval; investigate apparent failure for application technique, bathing, reinfection and resistance rather than empirically increasing dose.
  • For heartworm prevention, test according to local epidemiology and the exact label; heavily microfilaraemic dogs require veterinary assessment and monitoring for acute reactions.
Assessment sources
  1. VMD SPC 20252025
  2. FDA Revolution label2024
  3. Selamectin flea/HW field trials2000
  4. Selamectin mite field trials2000
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Full labelled species-specific scope for treatment or prevention of susceptible flea, mite, nematode and heartworm targets
8.6/10
Very good
vetman assessment

Stronghold

15 mg, selamectin 15 mg (60 mg/ml), spot-on solution for cats and dogs up to 2.5 kg
Assessed clinical scopeCat · Full labelled species-specific scope for treatment or prevention of susceptible flea, mite, nematode and heartworm targets · On the skin
Care settingMonthly or indication-specific single-pipette spot-on treatment after exact species, weight, parasite and heartworm-risk assessment
vetman score 8.6/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 274-11 · Verified on 15 Oct 2026

A mature, strongly supported broad endectocide for dogs and cats with convenient monthly topical dosing and well-defined species-specific label roles.

Regulatory and scientific credibility9.0/10

Every exact presentation is registered in Georgia and the reference product has mature current EU/UK and FDA authorisations.

Clinical efficacy9.0/10

Large randomized masked field programmes support high efficacy for fleas, heartworm prevention and labelled mite targets across dogs and cats, with extensive long-term clinical use.

Safety and tolerability8.0/10

The safety margin is well characterised and generally favourable, but species/weight mismatch, very young age, debilitated or underweight cats, wet or damaged skin, ingestion and heavily microfilaraemic dogs require specific precautions.

Clinical practicality8.5/10

A premeasured monthly pipette is simple and avoids oral administration, but correct skin exposure, full-pipette delivery, drying time and prevention of licking are necessary for reliable use.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only the exact species and weight-band pipette; do not split a pipette or substitute dog and cat presentations solely by milligram strength.
  • Do not use below six weeks of age or on wet, broken or otherwise unsuitable application skin; observe the locally applicable exact label.
  • Apply the complete pipette directly to exposed skin, prevent licking and close contact until dry, and keep away from flame or ignition sources during drying.
  • Confirm the target parasite and repeat interval; investigate apparent failure for application technique, bathing, reinfection and resistance rather than empirically increasing dose.
  • Do not use in cats with concomitant disease or in debilitated or underweight cats unless the exact locally applicable label and a veterinarian-led benefit-risk decision permit use.
Assessment sources
  1. VMD SPC 20252025
  2. FDA Revolution label2024
  3. Selamectin flea/HW field trials2000
  4. Selamectin mite field trials2000
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Selamectin15 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სტრონგჰოლდი - 15მგ დასაწვეთებელი ხსნარი ≤ 2.5კგ კატებისა და ძაღლებისათვის.
№ 274-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-152
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Stronghold 30 mg, Spot-on

selamectin 30 mg (120 mg/ml), spot-on solution for dogs 2.6-5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.6/10
Very good
vetman assessment

Stronghold

30 mg, selamectin 30 mg (120 mg/ml), spot-on solution for dogs 2.6-5 kg
Assessed clinical scopeDog · Full labelled species-specific scope for treatment or prevention of susceptible flea, mite, nematode and heartworm targets · On the skin
Care settingMonthly or indication-specific single-pipette spot-on treatment after exact species, weight, parasite and heartworm-risk assessment
vetman score 8.6/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 300-11 · Verified on 15 Oct 2026

A mature, strongly supported broad endectocide for dogs and cats with convenient monthly topical dosing and well-defined species-specific label roles.

Regulatory and scientific credibility9.0/10

Every exact presentation is registered in Georgia and the reference product has mature current EU/UK and FDA authorisations.

Clinical efficacy9.0/10

Large randomized masked field programmes support high efficacy for fleas, heartworm prevention and labelled mite targets across dogs and cats, with extensive long-term clinical use.

Safety and tolerability8.0/10

The safety margin is well characterised and generally favourable, but species/weight mismatch, very young age, debilitated or underweight cats, wet or damaged skin, ingestion and heavily microfilaraemic dogs require specific precautions.

Clinical practicality8.5/10

A premeasured monthly pipette is simple and avoids oral administration, but correct skin exposure, full-pipette delivery, drying time and prevention of licking are necessary for reliable use.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only the exact species and weight-band pipette; do not split a pipette or substitute dog and cat presentations solely by milligram strength.
  • Do not use below six weeks of age or on wet, broken or otherwise unsuitable application skin; observe the locally applicable exact label.
  • Apply the complete pipette directly to exposed skin, prevent licking and close contact until dry, and keep away from flame or ignition sources during drying.
  • Confirm the target parasite and repeat interval; investigate apparent failure for application technique, bathing, reinfection and resistance rather than empirically increasing dose.
  • For heartworm prevention, test according to local epidemiology and the exact label; heavily microfilaraemic dogs require veterinary assessment and monitoring for acute reactions.
Assessment sources
  1. VMD SPC 20252025
  2. FDA Revolution label2024
  3. Selamectin flea/HW field trials2000
  4. Selamectin mite field trials2000
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Selamectin30 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სტრონგჰოლდი - 30მგ დასაწვეთებელი ხსნარი 2,6-5,0კგ ძაღლებისთვის
№ 300-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-152
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Stronghold 45 mg, Spot-on

selamectin 45 mg (60 mg/ml), spot-on solution for cats 2.6-7.5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
8.6/10
Very good
vetman assessment

Stronghold

45 mg, selamectin 45 mg (60 mg/ml), spot-on solution for cats 2.6-7.5 kg
Assessed clinical scopeCat · Full labelled species-specific scope for treatment or prevention of susceptible flea, mite, nematode and heartworm targets · On the skin
Care settingMonthly or indication-specific single-pipette spot-on treatment after exact species, weight, parasite and heartworm-risk assessment
vetman score 8.6/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 303-12 · Verified on 15 Oct 2026

A mature, strongly supported broad endectocide for dogs and cats with convenient monthly topical dosing and well-defined species-specific label roles.

Regulatory and scientific credibility9.0/10

Every exact presentation is registered in Georgia and the reference product has mature current EU/UK and FDA authorisations.

Clinical efficacy9.0/10

Large randomized masked field programmes support high efficacy for fleas, heartworm prevention and labelled mite targets across dogs and cats, with extensive long-term clinical use.

Safety and tolerability8.0/10

The safety margin is well characterised and generally favourable, but species/weight mismatch, very young age, debilitated or underweight cats, wet or damaged skin, ingestion and heavily microfilaraemic dogs require specific precautions.

Clinical practicality8.5/10

A premeasured monthly pipette is simple and avoids oral administration, but correct skin exposure, full-pipette delivery, drying time and prevention of licking are necessary for reliable use.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only the exact species and weight-band pipette; do not split a pipette or substitute dog and cat presentations solely by milligram strength.
  • Do not use below six weeks of age or on wet, broken or otherwise unsuitable application skin; observe the locally applicable exact label.
  • Apply the complete pipette directly to exposed skin, prevent licking and close contact until dry, and keep away from flame or ignition sources during drying.
  • Confirm the target parasite and repeat interval; investigate apparent failure for application technique, bathing, reinfection and resistance rather than empirically increasing dose.
  • Do not use in cats with concomitant disease or in debilitated or underweight cats unless the exact locally applicable label and a veterinarian-led benefit-risk decision permit use.
Assessment sources
  1. VMD SPC 20252025
  2. FDA Revolution label2024
  3. Selamectin flea/HW field trials2000
  4. Selamectin mite field trials2000
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Selamectin45 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
Zoetis · United States
Manufacturer (register)
Zoetis Inc., United States
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 472, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სტრონგჰოლდი - 45მგ დასაწვეთებელი ხსნარი, 2,6-7,5კგ კატებისთვის
№ 303-12
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-152
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Stronghold 60 mg, Spot-on

selamectin 60 mg (120 mg/ml), spot-on solution for dogs 5.1-10 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.6/10
Very good
vetman assessment

Stronghold

60 mg, selamectin 60 mg (120 mg/ml), spot-on solution for dogs 5.1-10 kg
Assessed clinical scopeDog · Full labelled species-specific scope for treatment or prevention of susceptible flea, mite, nematode and heartworm targets · On the skin
Care settingMonthly or indication-specific single-pipette spot-on treatment after exact species, weight, parasite and heartworm-risk assessment
vetman score 8.6/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 302-11 · Verified on 15 Oct 2026

A mature, strongly supported broad endectocide for dogs and cats with convenient monthly topical dosing and well-defined species-specific label roles.

Regulatory and scientific credibility9.0/10

Every exact presentation is registered in Georgia and the reference product has mature current EU/UK and FDA authorisations.

Clinical efficacy9.0/10

Large randomized masked field programmes support high efficacy for fleas, heartworm prevention and labelled mite targets across dogs and cats, with extensive long-term clinical use.

Safety and tolerability8.0/10

The safety margin is well characterised and generally favourable, but species/weight mismatch, very young age, debilitated or underweight cats, wet or damaged skin, ingestion and heavily microfilaraemic dogs require specific precautions.

Clinical practicality8.5/10

A premeasured monthly pipette is simple and avoids oral administration, but correct skin exposure, full-pipette delivery, drying time and prevention of licking are necessary for reliable use.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only the exact species and weight-band pipette; do not split a pipette or substitute dog and cat presentations solely by milligram strength.
  • Do not use below six weeks of age or on wet, broken or otherwise unsuitable application skin; observe the locally applicable exact label.
  • Apply the complete pipette directly to exposed skin, prevent licking and close contact until dry, and keep away from flame or ignition sources during drying.
  • Confirm the target parasite and repeat interval; investigate apparent failure for application technique, bathing, reinfection and resistance rather than empirically increasing dose.
  • For heartworm prevention, test according to local epidemiology and the exact label; heavily microfilaraemic dogs require veterinary assessment and monitoring for acute reactions.
Assessment sources
  1. VMD SPC 20252025
  2. FDA Revolution label2024
  3. Selamectin flea/HW field trials2000
  4. Selamectin mite field trials2000
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Selamectin60 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სტრონგჰოლდი - 60მგ დასაწვეთებელი ხსნარი 5,1-10,0კგ ძაღლებისთვის
№ 302-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-152
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Stronghold 120 mg, Spot-on

selamectin 120 mg (120 mg/ml), spot-on solution for dogs 10.1-20 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.6/10
Very good
vetman assessment

Stronghold

120 mg, selamectin 120 mg (120 mg/ml), spot-on solution for dogs 10.1-20 kg
Assessed clinical scopeDog · Full labelled species-specific scope for treatment or prevention of susceptible flea, mite, nematode and heartworm targets · On the skin
Care settingMonthly or indication-specific single-pipette spot-on treatment after exact species, weight, parasite and heartworm-risk assessment
vetman score 8.6/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 277-11 · Verified on 15 Oct 2026

A mature, strongly supported broad endectocide for dogs and cats with convenient monthly topical dosing and well-defined species-specific label roles.

Regulatory and scientific credibility9.0/10

Every exact presentation is registered in Georgia and the reference product has mature current EU/UK and FDA authorisations.

Clinical efficacy9.0/10

Large randomized masked field programmes support high efficacy for fleas, heartworm prevention and labelled mite targets across dogs and cats, with extensive long-term clinical use.

Safety and tolerability8.0/10

The safety margin is well characterised and generally favourable, but species/weight mismatch, very young age, debilitated or underweight cats, wet or damaged skin, ingestion and heavily microfilaraemic dogs require specific precautions.

Clinical practicality8.5/10

A premeasured monthly pipette is simple and avoids oral administration, but correct skin exposure, full-pipette delivery, drying time and prevention of licking are necessary for reliable use.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only the exact species and weight-band pipette; do not split a pipette or substitute dog and cat presentations solely by milligram strength.
  • Do not use below six weeks of age or on wet, broken or otherwise unsuitable application skin; observe the locally applicable exact label.
  • Apply the complete pipette directly to exposed skin, prevent licking and close contact until dry, and keep away from flame or ignition sources during drying.
  • Confirm the target parasite and repeat interval; investigate apparent failure for application technique, bathing, reinfection and resistance rather than empirically increasing dose.
  • For heartworm prevention, test according to local epidemiology and the exact label; heavily microfilaraemic dogs require veterinary assessment and monitoring for acute reactions.
Assessment sources
  1. VMD SPC 20252025
  2. FDA Revolution label2024
  3. Selamectin flea/HW field trials2000
  4. Selamectin mite field trials2000
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Selamectin120 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
Zoetis · United States
Manufacturer (register)
Zoetis Inc., United States
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 463, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სტრონგჰოლდი - 120მგ დასაწვეთებელი ხსნარი, 10.1-20.0კგ ძაღლებისთვის.
№ 277-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-152
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Stronghold 240 mg, Spot-on

selamectin 240 mg (120 mg/ml), spot-on solution for dogs 20.1-40 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.6/10
Very good
vetman assessment

Stronghold

240 mg, selamectin 240 mg (120 mg/ml), spot-on solution for dogs 20.1-40 kg
Assessed clinical scopeDog · Full labelled species-specific scope for treatment or prevention of susceptible flea, mite, nematode and heartworm targets · On the skin
Care settingMonthly or indication-specific single-pipette spot-on treatment after exact species, weight, parasite and heartworm-risk assessment
vetman score 8.6/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 301-11 · Verified on 15 Oct 2026

A mature, strongly supported broad endectocide for dogs and cats with convenient monthly topical dosing and well-defined species-specific label roles.

Regulatory and scientific credibility9.0/10

Every exact presentation is registered in Georgia and the reference product has mature current EU/UK and FDA authorisations.

Clinical efficacy9.0/10

Large randomized masked field programmes support high efficacy for fleas, heartworm prevention and labelled mite targets across dogs and cats, with extensive long-term clinical use.

Safety and tolerability8.0/10

The safety margin is well characterised and generally favourable, but species/weight mismatch, very young age, debilitated or underweight cats, wet or damaged skin, ingestion and heavily microfilaraemic dogs require specific precautions.

Clinical practicality8.5/10

A premeasured monthly pipette is simple and avoids oral administration, but correct skin exposure, full-pipette delivery, drying time and prevention of licking are necessary for reliable use.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only the exact species and weight-band pipette; do not split a pipette or substitute dog and cat presentations solely by milligram strength.
  • Do not use below six weeks of age or on wet, broken or otherwise unsuitable application skin; observe the locally applicable exact label.
  • Apply the complete pipette directly to exposed skin, prevent licking and close contact until dry, and keep away from flame or ignition sources during drying.
  • Confirm the target parasite and repeat interval; investigate apparent failure for application technique, bathing, reinfection and resistance rather than empirically increasing dose.
  • For heartworm prevention, test according to local epidemiology and the exact label; heavily microfilaraemic dogs require veterinary assessment and monitoring for acute reactions.
Assessment sources
  1. VMD SPC 20252025
  2. FDA Revolution label2024
  3. Selamectin flea/HW field trials2000
  4. Selamectin mite field trials2000
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Selamectin240 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სტრონგჰოლდი - 240მგ დასაწვეთებელი ხსნარი 20.1-40,0კგ ძაღლებისთვის
№ 301-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-152
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Stronghold Plus 15 mg/2.5 mg, Spot-on

selamectin 15 mg + sarolaner 2.5 mg, spot-on solution for cats up to 2.5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
8.2/10
Very good
vetman assessment

Stronghold Plus

15 mg/2.5 mg, selamectin 15 mg + sarolaner 2.5 mg, spot-on solution for cats up to 2.5 kg
Assessed clinical scopeCat · Full labelled feline mixed-parasite scope when tick control and at least one other labelled target are required together: fleas, ticks, heartworm prevention, roundworms, hookworms, lice, ear mites and notoedric mange · On the skin
Care settingVeterinary-selected monthly or single-dose integrated parasite control based on the exact indication
vetman score 8.2/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 130-11 · Verified on 15 Oct 2026

A strong monthly feline endectoparasite option when tick control and another labelled target coincide; avoid the extra sarolaner component when tick treatment is not needed.

Regulatory and scientific credibility9.0/10

All three exact strengths have current transparent official SPCs and active Georgian veterinary registration, supported by multiple indication-specific field and controlled trials.

Clinical efficacy8.5/10

Field and controlled studies support strong monthly flea and tick control and high efficacy for labelled mites and other selamectin-sensitive parasites; the fixed combination is justified only when tick control and another target are needed together.

Safety and tolerability7.0/10

Usually well tolerated, but do not use in cats with concurrent disease or in debilitated, underweight animals; reproduction lacks combination safety data and rare neurologic reactions are possible with the isoxazoline component.

Clinical practicality8.5/10

A single colour-coded weight-band pipette is simple and monthly scheduling is clear, but it must reach dry skin, licking must be prevented and single-dose versus monthly indications must not be confused.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in cats with concurrent disease or in debilitated and underweight cats, or in hypersensitivity to either active substance or an excipient.
  • Use the fixed combination only when tick control and at least one other labelled parasite target are indicated at the same time.
  • Use only from 8 weeks of age and at least 1.25 kg; apply the exact pipette to dry skin at the neck and never into the ear canal or by mouth.
  • Combination safety is not established in breeding, pregnant or lactating cats; use only after an individual benefit-risk assessment.
Assessment sources
  1. VMD SPC 20252025
  2. Stronghold Plus field studies2017
  3. Stronghold Plus notoedres RCT2025
  4. Stronghold Plus tick RCT2017
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Selamectin15 mg Sarolaner2.5 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სტრონგჰოლდ პლუსი 15მგ/2.5მგ დასაწვეთებელი ხსნარი კატებისთვის ≤ 2.5კგ
№ 130-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-502
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Stronghold Plus 30 mg/5 mg, Spot-on

selamectin 30 mg + sarolaner 5 mg, spot-on solution for cats >2.5-5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
8.2/10
Very good
vetman assessment

Stronghold Plus

30 mg/5 mg, selamectin 30 mg + sarolaner 5 mg, spot-on solution for cats >2.5-5 kg
Assessed clinical scopeCat · Full labelled feline mixed-parasite scope when tick control and at least one other labelled target are required together: fleas, ticks, heartworm prevention, roundworms, hookworms, lice, ear mites and notoedric mange · On the skin
Care settingVeterinary-selected monthly or single-dose integrated parasite control based on the exact indication
vetman score 8.2/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 128-11 · Verified on 15 Oct 2026

A strong monthly feline endectoparasite option when tick control and another labelled target coincide; avoid the extra sarolaner component when tick treatment is not needed.

Regulatory and scientific credibility9.0/10

All three exact strengths have current transparent official SPCs and active Georgian veterinary registration, supported by multiple indication-specific field and controlled trials.

Clinical efficacy8.5/10

Field and controlled studies support strong monthly flea and tick control and high efficacy for labelled mites and other selamectin-sensitive parasites; the fixed combination is justified only when tick control and another target are needed together.

Safety and tolerability7.0/10

Usually well tolerated, but do not use in cats with concurrent disease or in debilitated, underweight animals; reproduction lacks combination safety data and rare neurologic reactions are possible with the isoxazoline component.

Clinical practicality8.5/10

A single colour-coded weight-band pipette is simple and monthly scheduling is clear, but it must reach dry skin, licking must be prevented and single-dose versus monthly indications must not be confused.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in cats with concurrent disease or in debilitated and underweight cats, or in hypersensitivity to either active substance or an excipient.
  • Use the fixed combination only when tick control and at least one other labelled parasite target are indicated at the same time.
  • Use only from 8 weeks of age and at least 1.25 kg; apply the exact pipette to dry skin at the neck and never into the ear canal or by mouth.
  • Combination safety is not established in breeding, pregnant or lactating cats; use only after an individual benefit-risk assessment.
Assessment sources
  1. VMD SPC 20252025
  2. Stronghold Plus field studies2017
  3. Stronghold Plus notoedres RCT2025
  4. Stronghold Plus tick RCT2017
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Selamectin30 mg Sarolaner5 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სტრონგჰოლდ პლუსი 30მგ/5მგ დასაწვეთებელი ხსნარი კატებისთვის > 2.5–5 კგ
№ 128-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-502
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Stronghold Plus 60 mg/10 mg, Spot-on

selamectin 60 mg + sarolaner 10 mg, spot-on solution for cats >5-10 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
8.2/10
Very good
vetman assessment

Stronghold Plus

60 mg/10 mg, selamectin 60 mg + sarolaner 10 mg, spot-on solution for cats >5-10 kg
Assessed clinical scopeCat · Full labelled feline mixed-parasite scope when tick control and at least one other labelled target are required together: fleas, ticks, heartworm prevention, roundworms, hookworms, lice, ear mites and notoedric mange · On the skin
Care settingVeterinary-selected monthly or single-dose integrated parasite control based on the exact indication
vetman score 8.2/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 127-11 · Verified on 15 Oct 2026

A strong monthly feline endectoparasite option when tick control and another labelled target coincide; avoid the extra sarolaner component when tick treatment is not needed.

Regulatory and scientific credibility9.0/10

All three exact strengths have current transparent official SPCs and active Georgian veterinary registration, supported by multiple indication-specific field and controlled trials.

Clinical efficacy8.5/10

Field and controlled studies support strong monthly flea and tick control and high efficacy for labelled mites and other selamectin-sensitive parasites; the fixed combination is justified only when tick control and another target are needed together.

Safety and tolerability7.0/10

Usually well tolerated, but do not use in cats with concurrent disease or in debilitated, underweight animals; reproduction lacks combination safety data and rare neurologic reactions are possible with the isoxazoline component.

Clinical practicality8.5/10

A single colour-coded weight-band pipette is simple and monthly scheduling is clear, but it must reach dry skin, licking must be prevented and single-dose versus monthly indications must not be confused.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in cats with concurrent disease or in debilitated and underweight cats, or in hypersensitivity to either active substance or an excipient.
  • Use the fixed combination only when tick control and at least one other labelled parasite target are indicated at the same time.
  • Use only from 8 weeks of age and at least 1.25 kg; apply the exact pipette to dry skin at the neck and never into the ear canal or by mouth.
  • Combination safety is not established in breeding, pregnant or lactating cats; use only after an individual benefit-risk assessment.
Assessment sources
  1. VMD SPC 20252025
  2. Stronghold Plus field studies2017
  3. Stronghold Plus notoedres RCT2025
  4. Stronghold Plus tick RCT2017
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Selamectin60 mg Sarolaner10 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
Zoetis · United States
Manufacturer (register)
Zoetis Inc., United States
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 834, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სტრონგჰოლდ პლუსი 60მგ/10მგ დასაწვეთებელი ხსნარი კატებისთვის > 5–10კგ
№ 127-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-502
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗